Skip to content
  • About
    • What we do
    • Our history
    • Our team
    • Our committees
    • Our partners
    • About genomics
  • Services
    • What we offer
    • Research we’re supporting
  • Tools & resources
    • Search all tools & resources
    • Research ethics & governance
    • Consent & patient support materials
    • Evaluating genomic research & translation
    • Data governance
    • Access our datasets
    • Data capture & standardisation
    • Data analysis & interpretation
    • Workforce education
    • Our publications
    • Our submissions
  • Our project areas
    • Our project areas
    • Genomic implementation projects 2022
    • Genomic information management
    • Clinical genomic practice
    • Genomic literacy, workforce & training
    • Indigenous genomic priorities
    • Genomic diagnostics
    • Evaluating genomic research & translation
    • Australian health system policy & practice
    • Involvement & engagement
  • News & events
    • News
    • Events
    • Personal stories
    • Search news & events
  • Connect with us

Whole-body MRI screening picks up early-stage cancers while still curable

Home All news & events News Whole-body MRI screening picks up early-stage…

An Australian and US research team, Dr Mandy Ballinger, Professor David Thomas (Garvan Institute of Medical Research), and Dr Ana Best and Dr Sharon Savage (National Cancer Institute, National Institutes of Health, USA) have shown conclusively that whole-body MRI detects primary cancers in people with an inherited cancer risk condition called Li-Fraumeni syndrome, at an early and curable stage, -at a rate of approximately one cancer per 10 individuals tested.

These findings are set to change clinical practice in monitoring those at high genetic risk of cancer and have been published today in leading cancer journal JAMA Oncology …continue reading at the Garvan Institute of Medical Research website.

Acknowledgement: Original article from the Garvan Institute of Medical Research.

Professor David Thomas (Director, Kinghorn Cancer Centre, Garvan Institute of Medical Research), leads the Australian Genomics cancer flagship, ‘Managing patient risk – AYA / PAED’. It aims to compare the genetic implications of patients recruited based on age-of-onset with family history, and to identify the spectrum of clinically actionable variants across a broad range of cancers, based on age of onset.